R
Revelation Biosciences D
D
REVB
1.29000
USD
-0.03
(-2.27%)
Market Closed
Volume
1,142
EPS
-4
Div Yield
-
P/E
0
Market Cap
3,383,822
Title: Revelation Biosciences Inc.
Sector: Healthcare
Industry: Biotechnology
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products basedon Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).